{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,4]],"date-time":"2026-11-04T22:31:59Z","timestamp":1793831519363,"version":"4.6.1"},"reference-count":47,"publisher":"Springer Science and Business Media LLC","issue":"8111","license":[{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T00:00:00Z","timestamp":1773792000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nature"],"published-print":{"date-parts":[[2026,4,23]]},"DOI":"10.1038\/s41586-026-10243-x","type":"journal-article","created":{"date-parts":[[2026,3,18]],"date-time":"2026-03-18T16:01:31Z","timestamp":1773849691000},"page":"995-1003","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":40,"title":["Thymic health and immunotherapy outcomes in patients with cancer"],"prefix":"10.1038","volume":"652","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-7758-8100","authenticated-orcid":false,"given":"Simon","family":"Bernatz","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-0623-1259","authenticated-orcid":false,"given":"Vasco","family":"Prudente","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Suraj","family":"Pai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0009-0006-3307-0031","authenticated-orcid":false,"given":"Asbj\u00f8rn K.","family":"Attermann","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandro","family":"Di Federico","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Andrew","family":"Rowan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Selvaraju","family":"Veeriah","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-7061-9851","authenticated-orcid":false,"given":"Lars","family":"Dyrskj\u00f8t","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6544-4268","authenticated-orcid":false,"given":"Leonard","family":"N\u00fcrnberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Joao V.","family":"Alessi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4253-943X","authenticated-orcid":false,"given":"Patrick A.","family":"Ott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Elad","family":"Sharon","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5570-5070","authenticated-orcid":false,"given":"Allan","family":"Hackshaw","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9537-4045","authenticated-orcid":false,"given":"Nicholas","family":"McGranahan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8983-1382","authenticated-orcid":false,"given":"Christopher","family":"Abbosh","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8754-0565","authenticated-orcid":false,"given":"Raymond H.","family":"Mak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Danielle","family":"Bitterman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Mark","family":"Awad","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Biagio","family":"Ricciuti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-4299-3018","authenticated-orcid":false,"given":"Charles","family":"Swanton","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1212-1259","authenticated-orcid":false,"given":"Mariam","family":"Jamal-Hanjani","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1613-9587","authenticated-orcid":false,"given":"Nicolai J.","family":"Birkbak","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2122-2003","authenticated-orcid":false,"given":"Hugo J. W. L.","family":"Aerts","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,3,18]]},"reference":[{"key":"10243_CR1","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0805-8","volume":"7","author":"S Das","year":"2019","unstructured":"Das, S. & Johnson, D. B. Immune-related adverse events and anti-tumor efficacy of immune checkpoint inhibitors. J. Immunother. Cancer 7, 306 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"10243_CR2","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1038\/s41577-020-0306-5","volume":"20","author":"AD Waldman","year":"2020","unstructured":"Waldman, A. D., Fritz, J. M. & Lenardo, M. J. A guide to cancer immunotherapy: from T cell basic science to clinical practice. Nat. Rev. Immunol. 20, 651\u2013668 (2020).","journal-title":"Nat. Rev. Immunol."},{"key":"10243_CR3","doi-asserted-by":"publisher","first-page":"6","DOI":"10.1038\/35005508","volume":"402","author":"AW Goldrath","year":"1999","unstructured":"Goldrath, A. W. & Bevan, M. J. Selecting and maintaining a diverse T-cell repertoire. Nature 402, 6\u201313 (1999).","journal-title":"Nature"},{"key":"10243_CR4","doi-asserted-by":"publisher","first-page":"1668","DOI":"10.1200\/JCO.2017.75.6270","volume":"36","author":"C Robert","year":"2018","unstructured":"Robert, C. et al. Durable complete response after discontinuation of pembrolizumab in patients with metastatic melanoma. J. Clin. Oncol. 36, 1668\u20131674 (2018).","journal-title":"J. Clin. Oncol."},{"key":"10243_CR5","doi-asserted-by":"publisher","first-page":"1718","DOI":"10.1016\/S0140-6736(22)00562-1","volume":"399","author":"JJ Luke","year":"2022","unstructured":"Luke, J. J. et al. Pembrolizumab versus placebo as adjuvant therapy in completely resected stage IIB or IIC melanoma (KEYNOTE-716): a randomised, double-blind, phase 3 trial. Lancet 399, 1718\u20131729 (2022).","journal-title":"Lancet"},{"key":"10243_CR6","doi-asserted-by":"publisher","first-page":"948","DOI":"10.1016\/S1470-2045(19)30151-2","volume":"20","author":"EA Rozeman","year":"2019","unstructured":"Rozeman, E. A. et al. Identification of the optimal combination dosing schedule of neoadjuvant ipilimumab plus nivolumab in macroscopic stage III melanoma (OpACIN-neo): a multicentre, phase 2, randomised, controlled trial. Lancet Oncol. 20, 948\u2013960 (2019).","journal-title":"Lancet Oncol."},{"key":"10243_CR7","doi-asserted-by":"publisher","first-page":"3323","DOI":"10.1200\/JCO.22.00825","volume":"40","author":"N Singh","year":"2022","unstructured":"Singh, N. et al. Therapy for stage IV non-small-cell lung cancer without driver alterations: ASCO living guideline. J. Clin. Oncol. 40, 3323\u20133343 (2022).","journal-title":"J. Clin. Oncol."},{"key":"10243_CR8","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1038\/s41585-020-0282-3","volume":"17","author":"W Xu","year":"2020","unstructured":"Xu, W., Atkins, M. B. & McDermott, D. F. Checkpoint inhibitor immunotherapy in kidney cancer. Nat. Rev. Urol. 17, 137\u2013150 (2020).","journal-title":"Nat. Rev. Urol."},{"key":"10243_CR9","doi-asserted-by":"publisher","first-page":"1789","DOI":"10.1056\/NEJMoa1802357","volume":"378","author":"AMM Eggermont","year":"2018","unstructured":"Eggermont, A. M. M. et al. Adjuvant pembrolizumab versus placebo in resected stage III melanoma. N. Engl. J. Med. 378, 1789\u20131801 (2018).","journal-title":"N. Engl. J. Med."},{"key":"10243_CR10","doi-asserted-by":"publisher","first-page":"23","DOI":"10.1056\/NEJMoa1504030","volume":"373","author":"J Larkin","year":"2015","unstructured":"Larkin, J. et al. Combined nivolumab and ipilimumab or monotherapy in untreated melanoma. N. Engl. J. Med. 373, 23\u201334 (2015).","journal-title":"N. Engl. J. Med."},{"key":"10243_CR11","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann, M. D. et al. Nivolumab plus ipilimumab in advanced non-small-cell lung cancer. N. Engl. J. Med. 381, 2020\u20132031 (2019).","journal-title":"N. Engl. J. Med."},{"key":"10243_CR12","doi-asserted-by":"publisher","DOI":"10.1186\/s40425-019-0768-9","volume":"7","author":"AA Davis","year":"2019","unstructured":"Davis, A. A. & Patel, V. G. The role of PD-L1 expression as a predictive biomarker: an analysis of all US Food and Drug Administration (FDA) approvals of immune checkpoint inhibitors. J. Immunother. Cancer 7, 278 (2019).","journal-title":"J. Immunother. Cancer"},{"key":"10243_CR13","doi-asserted-by":"publisher","first-page":"202","DOI":"10.1038\/s41588-018-0312-8","volume":"51","author":"RM Samstein","year":"2019","unstructured":"Samstein, R. M. et al. Tumor mutational load predicts survival after immunotherapy across multiple cancer types. Nat. Genet. 51, 202\u2013206 (2019).","journal-title":"Nat. Genet."},{"key":"10243_CR14","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-022-01136-2","volume":"7","author":"D-R Wang","year":"2022","unstructured":"Wang, D.-R., Wu, X.-L. & Sun, Y.-L. Therapeutic targets and biomarkers of tumor immunotherapy: response versus non-response. Signal Transduct. Target. Ther. 7, 331 (2022).","journal-title":"Signal Transduct. Target. Ther."},{"key":"10243_CR15","doi-asserted-by":"publisher","first-page":"883","DOI":"10.1056\/NEJMoa1113205","volume":"366","author":"M Gerlinger","year":"2012","unstructured":"Gerlinger, M. et al. Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N. Engl. J. Med. 366, 883\u2013892 (2012).","journal-title":"N. Engl. J. Med."},{"key":"10243_CR16","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1016\/j.lungcan.2019.06.005","volume":"134","author":"A Haragan","year":"2019","unstructured":"Haragan, A. et al. Heterogeneity of PD-L1 expression in non-small cell lung cancer: Implications for specimen sampling in predicting treatment response. Lung Cancer 134, 79\u201384 (2019).","journal-title":"Lung Cancer"},{"key":"10243_CR17","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.603157","volume":"11","author":"S Li","year":"2020","unstructured":"Li, S., Zhang, C., Pang, G. & Wang, P. Emerging blood-based biomarkers for predicting response to checkpoint immunotherapy in non-small-cell lung cancer. Front. Immunol. 11, 603157 (2020).","journal-title":"Front. Immunol."},{"key":"10243_CR18","doi-asserted-by":"publisher","first-page":"2112","DOI":"10.1038\/s41588-024-01899-0","volume":"56","author":"J Usset","year":"2024","unstructured":"Usset, J. et al. Five latent factors underlie response to immunotherapy. Nat. Genet. 56, 2112\u20132120 (2024).","journal-title":"Nat. Genet."},{"key":"10243_CR19","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.00773","volume":"11","author":"W Wang","year":"2020","unstructured":"Wang, W., Thomas, R., Sizova, O. & Su, D. M. Thymic function associated with cancer development, relapse, and antitumor immunity \u2013 a mini-review. Front. Immunol. 11, 773 (2020).","journal-title":"Front. Immunol."},{"key":"10243_CR20","doi-asserted-by":"publisher","first-page":"406","DOI":"10.1056\/NEJMoa2302892","volume":"389","author":"KA Kooshesh","year":"2023","unstructured":"Kooshesh, K. A., Foy, B. H., Sykes, D. B., Gustafsson, K. & Scadden, D. T. Health consequences of thymus removal in adults. N. Engl. J. Med. 389, 406\u2013417 (2023).","journal-title":"N. Engl. J. Med."},{"key":"10243_CR21","doi-asserted-by":"publisher","first-page":"3100","DOI":"10.1038\/s41591-023-02591-2","volume":"29","author":"C Fenioux","year":"2023","unstructured":"Fenioux, C. et al. Thymus alterations and susceptibility to immune checkpoint inhibitor myocarditis. Nat. Med. 29, 3100\u20133110 (2023).","journal-title":"Nat. Med."},{"key":"10243_CR22","doi-asserted-by":"publisher","first-page":"916","DOI":"10.1158\/2159-8290.CD-20-1559","volume":"11","author":"C Bailey","year":"2021","unstructured":"Bailey, C. et al. Tracking cancer evolution through the disease course. Cancer Discov. 11, 916\u2013932 (2021).","journal-title":"Cancer Discov."},{"key":"10243_CR23","doi-asserted-by":"publisher","first-page":"690","DOI":"10.1038\/25374","volume":"396","author":"DC Douek","year":"1998","unstructured":"Douek, D. C. et al. Changes in thymic function with age and during the treatment of HIV infection. Nature 396, 690\u2013695 (1998).","journal-title":"Nature"},{"key":"10243_CR24","doi-asserted-by":"publisher","DOI":"10.1186\/s12979-023-00371-7","volume":"20","author":"M Sandstedt","year":"2023","unstructured":"Sandstedt, M. et al. Complete fatty degeneration of thymus associates with male sex, obesity and loss of circulating na\u00efve CD8+ T cells in a Swedish middle-aged population. Immun. Ageing 20, 45 (2023).","journal-title":"Immun. Ageing"},{"key":"10243_CR25","doi-asserted-by":"publisher","first-page":"1549","DOI":"10.1038\/s41591-019-0592-2","volume":"25","author":"K Joshi","year":"2019","unstructured":"Joshi, K. et al. Spatial heterogeneity of the T cell receptor repertoire reflects the mutational landscape in lung cancer. Nat. Med. 25, 1549\u20131559 (2019).","journal-title":"Nat. Med."},{"key":"10243_CR26","doi-asserted-by":"publisher","first-page":"555","DOI":"10.1038\/s41586-021-03894-5","volume":"597","author":"R Bentham","year":"2021","unstructured":"Bentham, R. et al. Using DNA sequencing data to quantify T cell fraction and therapy response. Nature 597, 555\u2013560 (2021).","journal-title":"Nature"},{"key":"10243_CR27","doi-asserted-by":"publisher","first-page":"846","DOI":"10.1038\/s41591-023-02232-8","volume":"29","author":"O Al-Sawaf","year":"2023","unstructured":"Al-Sawaf, O. et al. Body composition and lung cancer-associated cachexia in TRACERx. Nat. Med. 29, 846\u2013858 (2023).","journal-title":"Nat. Med."},{"key":"10243_CR28","doi-asserted-by":"publisher","first-page":"D638","DOI":"10.1093\/nar\/gkac1000","volume":"51","author":"D Szklarczyk","year":"2023","unstructured":"Szklarczyk, D. et al. The STRING database in 2023: protein\u2013protein association networks and functional enrichment analyses for any sequenced genome of interest. Nucleic Acids Res. 51, D638\u2013D646 (2023).","journal-title":"Nucleic Acids Res."},{"key":"10243_CR29","doi-asserted-by":"publisher","first-page":"2076","DOI":"10.1158\/0008-5472.CAN-21-2542","volume":"82","author":"N Sinha","year":"2022","unstructured":"Sinha, N. et al. Immune determinants of the association between tumor mutational burden and immunotherapy response across cancer types. Cancer Res. 82, 2076\u20132083 (2022).","journal-title":"Cancer Res."},{"key":"10243_CR30","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01745","volume":"11","author":"S Kinsella","year":"2020","unstructured":"Kinsella, S. & Dudakov, J. A. When the damage is done: injury and repair in thymus function. Front. Immunol. 11, 1745 (2020).","journal-title":"Front. Immunol."},{"key":"10243_CR31","doi-asserted-by":"publisher","first-page":"2113","DOI":"10.1056\/NEJMoa2210233","volume":"387","author":"MW Rohaan","year":"2022","unstructured":"Rohaan, M. W. et al. Tumor-infiltrating lymphocyte therapy or ipilimumab in advanced melanoma. N. Engl. J. Med. 387, 2113\u20132125 (2022).","journal-title":"N. Engl. J. Med."},{"key":"10243_CR32","doi-asserted-by":"publisher","first-page":"162","DOI":"10.1038\/s41586-024-07238-x","volume":"628","author":"JB Ross","year":"2024","unstructured":"Ross, J. B. et al. Depleting myeloid-biased haematopoietic stem cells rejuvenates aged immunity. Nature 628, 162\u2013170 (2024).","journal-title":"Nature"},{"key":"10243_CR33","first-page":"1085","volume":"118","author":"LA Napolitano","year":"2008","unstructured":"Napolitano, L. A. et al. Growth hormone enhances thymic function in HIV-1-infected adults. J. Clin. Invest. 118, 1085\u20131098 (2008).","journal-title":"J. Clin. Invest."},{"key":"10243_CR34","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2021.706244","volume":"12","author":"M Duah","year":"2021","unstructured":"Duah, M. et al. Thymus degeneration and regeneration. Front. Immunol. 12, 706244 (2021).","journal-title":"Front. Immunol."},{"key":"10243_CR35","doi-asserted-by":"publisher","first-page":"1883","DOI":"10.1073\/pnas.1714478115","volume":"115","author":"S Palmer","year":"2018","unstructured":"Palmer, S., Albergante, L., Blackburn, C. C. & Newman, T. J. Thymic involution and rising disease incidence with age. Proc. Natl Acad. Sci. USA 115, 1883\u20131888 (2018).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"10243_CR36","doi-asserted-by":"publisher","DOI":"10.1186\/s12979-020-0173-8","volume":"17","author":"R Thomas","year":"2020","unstructured":"Thomas, R., Wang, W. & Su, D.-M. Contributions of age-related thymic involution to immunosenescence and inflammaging. Immun. Ageing 17, 2 (2020).","journal-title":"Immun. Ageing"},{"key":"10243_CR37","doi-asserted-by":"publisher","first-page":"15","DOI":"10.1007\/s00330-015-3796-y","volume":"26","author":"T Araki","year":"2016","unstructured":"Araki, T. et al. Normal thymus in adults: appearance on CT and associations with age, sex, BMI and smoking. Eur. Radiol. 26, 15\u201324 (2016).","journal-title":"Eur. Radiol."},{"key":"10243_CR38","doi-asserted-by":"publisher","first-page":"245","DOI":"10.1148\/radiol.13121104","volume":"268","author":"JB Ackman","year":"2013","unstructured":"Ackman, J. B. et al. Sex difference in normal thymic appearance in adults 20-30 years of age. Radiology 268, 245\u2013253 (2013).","journal-title":"Radiology"},{"key":"10243_CR39","doi-asserted-by":"publisher","unstructured":"Bernatz, S. et al. Thymic health consequences in adults. Nature https:\/\/doi.org\/10.1038\/s41586-026-10242-y (2026).","DOI":"10.1038\/s41586-026-10242-y"},{"key":"10243_CR40","doi-asserted-by":"publisher","DOI":"10.1111\/acel.12750","volume":"17","author":"NA Duggal","year":"2018","unstructured":"Duggal, N. A., Pollock, R. D., Lazarus, N. R., Harridge, S. & Lord, J. M. Major features of immunesenescence, including reduced thymic output, are ameliorated by high levels of physical activity in adulthood. Aging Cell 17, e12750 (2018).","journal-title":"Aging Cell"},{"key":"10243_CR41","doi-asserted-by":"publisher","first-page":"56","DOI":"10.1111\/imr.12418","volume":"271","author":"MS Chaudhry","year":"2016","unstructured":"Chaudhry, M. S., Velardi, E., Dudakov, J. A. & van den Brink, M. R. M. Thymus: the next (re)generation. Immunol. Rev. 271, 56\u201371 (2016).","journal-title":"Immunol. Rev."},{"key":"10243_CR42","doi-asserted-by":"publisher","first-page":"2109","DOI":"10.1056\/NEJMoa1616288","volume":"376","author":"M Jamal-Hanjani","year":"2017","unstructured":"Jamal-Hanjani, M. et al. Tracking the evolution of non-small-cell lung cancer. N. Engl. J. Med. 376, 2109\u20132121 (2017).","journal-title":"N. Engl. J. Med."},{"key":"10243_CR43","doi-asserted-by":"publisher","first-page":"525","DOI":"10.1038\/s41586-023-05783-5","volume":"616","author":"AM Frankell","year":"2023","unstructured":"Frankell, A. M. et al. The evolution of lung cancer and impact of subclonal selection in TRACERx. Nature 616, 525\u2013533 (2023).","journal-title":"Nature"},{"key":"10243_CR44","doi-asserted-by":"publisher","first-page":"502","DOI":"10.1016\/j.it.2013.06.004","volume":"34","author":"C Nunes-Alves","year":"2013","unstructured":"Nunes-Alves, C., Nobrega, C., Behar, S. M. & Correia-Neves, M. Tolerance has its limits: how the thymus copes with infection. Trends Immunol. 34, 502\u2013510 (2013).","journal-title":"Trends Immunol."},{"key":"10243_CR45","doi-asserted-by":"publisher","first-page":"542","DOI":"10.1093\/bioinformatics\/btt004","volume":"29","author":"N Thomas","year":"2013","unstructured":"Thomas, N., Heather, J., Ndifon, W., Shawe-Taylor, J. & Chain, B. Decombinator: a tool for fast, efficient gene assignment in T-cell receptor sequences using a finite state machine. Bioinformatics 29, 542\u2013550 (2013).","journal-title":"Bioinformatics"},{"key":"10243_CR46","doi-asserted-by":"publisher","first-page":"D672","DOI":"10.1093\/nar\/gkad1025","volume":"52","author":"M Milacic","year":"2024","unstructured":"Milacic, M. et al. The Reactome Pathway Knowledgebase 2024. Nucleic Acids Res. 52, D672\u2013D678 (2024).","journal-title":"Nucleic Acids Res."},{"key":"10243_CR47","doi-asserted-by":"publisher","unstructured":"Prudente, V. C. G. et al. Resources \u201cThymic health and immunotherapy outcomes in patients with cancer\u201d. Zenodo https:\/\/doi.org\/10.5281\/zenodo.18330021 (2026).","DOI":"10.5281\/zenodo.18330021"}],"container-title":["Nature"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10243-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10243-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10243-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,5,21]],"date-time":"2026-05-21T15:02:33Z","timestamp":1779375753000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s41586-026-10243-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,3,18]]},"references-count":47,"journal-issue":{"issue":"8111","published-print":{"date-parts":[[2026,4,23]]}},"alternative-id":["10243"],"URL":"https:\/\/doi.org\/10.1038\/s41586-026-10243-x","relation":{},"ISSN":["0028-0836","1476-4687"],"issn-type":[{"value":"0028-0836","type":"print"},{"value":"1476-4687","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,3,18]]},"assertion":[{"value":"13 January 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"5 February 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 March 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"M.J.-H. has consulted for Astex Pharmaceutical and Achilles Therapeutics, is a member of the Achilles Therapeutics scientific advisory board (SAB) and steering committee and has received speaker honoraria from Pfizer, Astex Pharmaceuticals, Oslo Cancer Cluster, Bristol Myers Squibb and Genentech. M.J.-H. is listed as a co-inventor on a European patent application relating to methods to detect lung cancer (PCT\/US2017\/028013); this patent has been licensed to commercial entities and, under terms of employment, M.J.-H. is due a share of any revenue generated from such licence(s). M.J.-H. is also listed as a co-inventor on a GB priority patent application (GB2400424.4: \u2018Treatment and Prevention of Lung Cancer\u2019). C.S. has received support from the Francis Crick Institute and the Royal Society; has received grants or contracts from AstraZeneca, Boehringer Ingelheim, Bristol Myers Squibb, Invitae (formerly Archer Dx), Ono Pharmaceuticals, Pfizer and Roche-Ventana; has received consulting fees from Bicycle Therapeutics, Genentech, Medicxi, Metabomed and Novartis; is a member of the GRAIL SAB, the Relay Therapeutics SAB, China Innovation Centre of Roche (CICoR), the SAGA Diagnostics SAB and the Sarah Cannon Research Institute; has received honoraria from Amgen, AstraZeneca, Bristol Myers Squibb, Illumina, GlaxoSmithKline, MSD, Roche-Ventana and Pfizer; holds patents, planned, issued or pending, including PCT\/GB2017\/053289, PCT\/EP2016\/059401, PCT\/EP2016\/071471, PCT\/GB2018\/052004, PCT\/GB2020\/050221, PCT\/GB2018\/051912, PCT\/US2017\/28013 and PCT\/GB2018\/051892; has leadership or fiduciary roles with Cancer Research UK and the American Association for Cancer Research (AACR); holds stock or stock options in ApoGen Biotech, Epic Biosciences, GRAIL and Achilles Therapeutics; and has other financial or non-financial interests with AstraZeneca and GRAIL Bio UK. N.M. holds patents related to determining human leukocyte antigen (HLA) loss of heterozygosity (LOH) (PCT\/GB2018\/052004), determining the B cell fraction in mixed samples (PCT\/EP2024\/062999), determining lymphocyte abundance in mixed samples (PCT\/EP2022\/070694), identifying responders to cancer treatment (PCT\/GB2018\/051912), targeting neoantigens (PCT\/EP2016\/059401), identifying patient response to immune checkpoint blockade (PCT\/EP2016\/071471) and predicting survival rates of patients with cancer (PCT\/GB2020\/050221), and has a patent pending in determining HLA disruption (PCT\/EP2023\/059039). S.V. is a co-inventor on a patent of methods for detecting molecules in a sample (US 10,578,620). A.H. has received fees for being a member of independent data monitoring committees for Roche-sponsored clinical trials and academic projects coordinated by Roche. S.B. reports consulting fees from Ambient. N.J.B. reports consulting fees from Ambient and is listed as a co-inventor on a patent application (PCT\/GB2020\/050221) on methods for cancer prognostication and a patent on methods for predicting anti-cancer response (US14\/466,208). H.J.W.L.A. reports consulting fees and\/or stock from Onc.AI, Love Health, Sphera, HealthAI, Ambient and AstraZeneca. R.H.M.: advisory board (ViewRay and AstraZeneca), consulting (AstraZeneca, Varian Medical Systems, Sio Capital Management and Pfizer), honoraria (Novartis, Springer Nature), research funding (NIH, ViewRay, AstraZeneca, Siemens Medical Solutions USA and Varian Medical Systems). D.B. is a member of the MercurialAI SAB. L.D. has sponsored research agreements with C2i Genomics, Natera, AstraZeneca, Photocure and Ferring; an advisory or consulting role at Ferring, MSD, Cystotech and UroGen;\u00a0and has received speaker honoraria from AstraZeneca, Pfizer and Roche and travel support from MSD. A.D.F. reports fees and advisory fees from Novartis, IQVIA and Hanson-Wade. C.A. is an employee of Astrazeneca and owns stocks in Astrazeneca; and\u00a0holds patents\/patent applications in minimal residual disease detection (PCT\/GB2017\/053289, PCT\/US2017\/028013 and PCT\/EP2022\/077987).\u00a0The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}